{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T22:56:11Z","timestamp":1777416971841,"version":"3.51.4"},"reference-count":43,"publisher":"SAGE Publications","issue":"11","license":[{"start":{"date-parts":[[1985,11,1]],"date-time":"1985-11-01T00:00:00Z","timestamp":499651200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Intelligence &amp; Clinical Pharmacy"],"published-print":{"date-parts":[[1985,11]]},"abstract":"<jats:p>The phenothiazines have exhibited a history of problems associated with the bioequivalence of solid oral dosage forms. The more recent availability of chemically equivalent forms of thioridazine has raised new and interesting questions about the appropriateness of generic product interchange, even among brands that have been designated \u201ctherapeutically equivalent\u201d by the Food and Drug Administration. The scrutiny that has accompanied the consideration of thioridazine products for inclusion into various state generic substitution formularies has offered an opportunity to examine issues involving bioequivalency in considerable detail. Specific bioequivalency concerns relate to: Correct analysis of drug in biological fluids; the importance of evaluating active metabolites; single-dose vs. multiple-dose crossover studies; appropriate statistical power analysis; the \u201c70\/70\u201d rule, and comparison of product variabilities. Examples of problems are cited to illustrate that significant questions still remain about the appropriate factors that should be used to establish bioequivalency.<\/jats:p>","DOI":"10.1177\/106002808501901124","type":"journal-article","created":{"date-parts":[[2016,5,11]],"date-time":"2016-05-11T11:24:23Z","timestamp":1462965863000},"page":"847-858","source":"Crossref","is-referenced-by-count":7,"title":["Critical Evaluation of Thioridazine Bioequivalence"],"prefix":"10.1177","volume":"19","author":[{"given":"Joseph A.","family":"Barone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John L.","family":"Colaizzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[1985,11,1]]},"reference":[{"key":"bibr1-106002808501901124","volume-title":"Poisindex","author":"Barone J.","year":"1984"},{"key":"bibr2-106002808501901124","unstructured":"Phenothiazines general statement. In: McEvoy GK, Mcquarrie GM, eds. American hospital formulary service drug information 85. Bethesda, MD: American Society of Hospital Pharmacists, Inc. 1985: 861\u20136."},{"key":"bibr3-106002808501901124","first-page":"152","volume-title":"The pharmacological basis of therapeutics","author":"Byck R.","year":"1975","edition":"5"},{"key":"bibr4-106002808501901124","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pa.16.040176.000413"},{"key":"bibr5-106002808501901124","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S0022-3565(25)30358-7","volume":"195","author":"Smolen VF","year":"1975","journal-title":"J Pharmacol Exp Ther"},{"key":"bibr6-106002808501901124","first-page":"56832","volume":"45","author":"Halperin JA","year":"1980","journal-title":"Federal Register"},{"key":"bibr7-106002808501901124","unstructured":"Drug price control and patent term restoration act. The Congressional Record, Washington, DC, September 12, 1984: 10981."},{"key":"bibr8-106002808501901124","first-page":"156","volume":"84","author":"Twenty discoveries","year":"1984","journal-title":"Science"},{"key":"bibr9-106002808501901124","first-page":"141","volume":"9","author":"Snyder SH","year":"1984","journal-title":"Science 84"},{"key":"bibr10-106002808501901124","volume-title":"Interchangeable drug products; the drug utilization review council formulary","year":"1982","edition":"4"},{"key":"bibr11-106002808501901124","doi-asserted-by":"publisher","DOI":"10.1177\/106002807300700905"},{"key":"bibr12-106002808501901124","first-page":"529","volume":"33","author":"Bankier RG","year":"1972","journal-title":"Dis Nerv Syst"},{"key":"bibr13-106002808501901124","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1975.tb02338.x"},{"key":"bibr14-106002808501901124","unstructured":"Approved prescription drug products with therapeutic equivalence evaluations, 5th ed. Rockville, MD: U.S. Dept. of Health and Human Services, Public Health Service, Food and Drug Administration, Bureau of Drugs, 1984: 41\u20132, 164\u20135, 192\u20133, 198."},{"key":"bibr15-106002808501901124","unstructured":"Wagner JG. Fundamentals of clinical pharmacokinetics. Hamilton, IL: Drug Intelligence Publications, Inc. 1975: 340\u20131."},{"key":"bibr16-106002808501901124","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1977214437"},{"key":"bibr17-106002808501901124","first-page":"9","volume":"16","author":"American College of Neuropsychopharmacology","year":"1980","journal-title":"Psychopharmacol Bull"},{"key":"bibr18-106002808501901124","doi-asserted-by":"publisher","DOI":"10.1177\/106002808401800915"},{"key":"bibr19-106002808501901124","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2.3.33"},{"key":"bibr20-106002808501901124","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1984.tb05846.x"},{"key":"bibr21-106002808501901124","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-197803010-00002"},{"key":"bibr22-106002808501901124","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0773.1982.tb00935.x"},{"key":"bibr23-106002808501901124","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(00)81862-9"},{"key":"bibr24-106002808501901124","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(00)84122-5"},{"key":"bibr25-106002808501901124","first-page":"152","volume-title":"Program and abstracts of the 37th national meeting of the American Pharmaceutical Association Academy of Pharmaceutical Sciences","author":"Viswanathan CT","year":"1984"},{"key":"bibr26-106002808501901124","first-page":"561","volume":"21","author":"Axelsson R.","year":"1977","journal-title":"Curr Ther Res"},{"key":"bibr27-106002808501901124","first-page":"87","volume-title":"Pharmacology and pharmacokinetics","author":"Riegelman S.","year":"1974"},{"key":"bibr28-106002808501901124","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1982.1"},{"key":"bibr29-106002808501901124","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.136.6.591"},{"key":"bibr30-106002808501901124","first-page":"171","volume-title":"Pharmacokinetics of psychoactive drugs","author":"Gottschalk LA","year":"1976"},{"key":"bibr31-106002808501901124","first-page":"520","volume":"7","author":"Sugarman AA","year":"1965","journal-title":"Curr Ther Res"},{"key":"bibr32-106002808501901124","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0022-3565(25)32494-8","volume":"217","author":"Bylund DB","year":"1981","journal-title":"J Pharmacol Exp Ther"},{"key":"bibr33-106002808501901124","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S0022-3565(25)21884-5","volume":"228","author":"Niedzwiecki DM","year":"1984","journal-title":"J Pharmacol Exp Ther"},{"key":"bibr34-106002808501901124","doi-asserted-by":"publisher","DOI":"10.1007\/BF00562905"},{"key":"bibr35-106002808501901124","first-page":"115","volume-title":"Drug absorption and disposition: Statistical considerations","author":"Purich E.","year":"1980"},{"key":"bibr36-106002808501901124","first-page":"109","volume":"1","author":"Metzler CM","year":"1983","journal-title":"Clin Res Pract Drug Reg Affairs"},{"key":"bibr37-106002808501901124","unstructured":"Wagner JG. Fundamentals of clinical pharmacokinetics. Hamilton, IL: Drug Intelligence Publications, Inc. 1975: 301\u20136."},{"key":"bibr38-106002808501901124","unstructured":"Dixon WJ, Massey FJ. Introduction to statistical analysis, 2nd ed. New York: McGraw-Hill, 1957: 244\u201361."},{"key":"bibr39-106002808501901124","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600700625"},{"key":"bibr40-106002808501901124","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600720127"},{"key":"bibr41-106002808501901124","unstructured":"Snedecor GW, Cochran WG. Statistical methods, 7th ed. Iowa City: The Iowa State University Press, 1980: 190\u20131."},{"key":"bibr42-106002808501901124","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600720128"},{"key":"bibr43-106002808501901124","first-page":"189","volume-title":"Program and abstracts of the 37th national meeting of the American Pharmaceutical Association Academy of Pharmaceutical Sciences","author":"Hwang DS","year":"1984"}],"container-title":["Drug Intelligence &amp; Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/106002808501901124","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/106002808501901124","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:03:04Z","timestamp":1777374184000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/106002808501901124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1985,11]]},"references-count":43,"journal-issue":{"issue":"11","published-print":{"date-parts":[[1985,11]]}},"alternative-id":["10.1177\/106002808501901124"],"URL":"https:\/\/doi.org\/10.1177\/106002808501901124","relation":{},"ISSN":["0012-6578"],"issn-type":[{"value":"0012-6578","type":"print"}],"subject":[],"published":{"date-parts":[[1985,11]]}}}